logo-loader

Feedback advancing clinical use of TexRAD after bagging CE mark

Published: 14:05 23 Nov 2017 GMT

Alastair Riddell, chairman of Feedback plc (LON:FDBK) tells Proactive they're now able to crack on with expanding the clinical use of  TexRAD in the treatment of lung cancer across the EU after finally receiving a CE mark for the technology earlier this week.

The award of the CE mark means Feedback can now sell TexRAD Lung to hospitals, satisfying the quality, safety and performance standards required for medical devices in the European Union.

This particular version of the product will help doctors diagnose and treat people with lung cancer, the most common and most deadly form of the disease.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

30 minutes ago